Cautious Optimism: The State of Clinical Research in 2025

In this episode, host Jeremy Schrand is joined by Tim Schroeder, Chairman, CEO, and Founder of CTI, and Joel White, Owner of Marketcap Consulting, for a broad discussion on the clinical research industry. Topics include recent industry developments, biotech funding challenges, leadership in clinical trials, corporate citizenship, and predictions for future innovation.

01:20 Tim shares insights on the current state ofthe clinical research industry, highlighting recent developments and a view toward stability and cautious optimism.

02:36 Joe discusses macro trends shaping the clinical research landscape, focusing on biotech funding challenges and the impact on the industry.

04:05 The conversation shifts to the pharma services sector, with Joe reflecting on the changing number of public companies and the influence of major investment firms.

06:53 The conversation explores industry cancellation rates and repeat business, leading to a discussion on measurement differences and the challenges of consistent reporting.

08:08 The role of leadership in navigating today's complex clinical trial environment is explored, emphasizing vision, talent retention, and cultural impact.

13:08 Tim and Joel discuss corporate citizenship, leading to reflections on CTI’s evolution, community involvement, and the importance of sustainability.

21:01 Exploring the potential influence of major retail companies on the clinical trial ecosphere, the conversation considers their resources and the challenges they face within the industry.

22:34 Tim addresses therapeutic areas with recent surges in activity or innovation, prompting a discussion on oncology,neurodegeneration, and GLP therapies.

29:00 Bold predictions shape the future of the clinical research industry, with forecasts pointing to a recovery in biotech funding and shifts in FDA approval processes.